Tests acalabrutinib with venetoclax in adults whose leukemia has returned
Tests acalabrutinib and venetoclax in adults with CLL or SLL that came back after treatment.
Plain-language title generated from the registry record
Registry title: MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Key facts
- Where
- Meldola, Milan, Padova, and Ravenna, ItalySee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT07024706, who can take part
Where in Italy
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.lMeldola, ItalyTaking people
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
- Azienda Ospedaliera di PadovaPadova, ItalyTaking people
- Azienda Unità Sanitaria Locale della RomagnaRavenna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07024706EU 2024-518858-17-00
- Record updated
- 23 October 2026
- Original description
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.Read full original descriptionShow less
The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Main Inclusion Criteria:; Participant must be ≥ 18 years at the time of signing informed consent; Diagnosis of relapsed CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018) in need of treatment; Participants must have received only one prior first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) for a minimum of 2 years since the end of the prior 1L treatment; The following data must be available or at least the appropriate samples drawn/acquired prior to dosing:; IGHV (mutated vs. unmutated); del(17p) (present or absent); TP53 mutation (present or absent); ECOG performance status 0, 1 or 2; Adequate organ and bone marrow (BM) function; Main Exclusion Criteria:; Any evidence of diseases that, in the investigator's opinion, makes it undesirable for patient to participate in the study; Significant cardiovascular or cerebrovascular disease; Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease); Child-Pugh B/C liver cirrhosis; History of prior or current malignancy; HIV positive; History of progressive multifocal leukoencephalopathy (PML); Active hepatitis B or C infection:; Corticosteroid use > 20 mg within 1 week before the first dose of study intervention; History of hypersensitivity or anaphylaxis to study intervention(s); Requires treatment with a strong CYP3A4 inhibitor/inducer; Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists; Major surgical procedure within 30 days of the first dose of study intervention.